title: Peritonitis-induced antitumor activity of peritoneal macrophages from uremic patients.
abstract: The macrophages belong to the effector cells of both nonspecific and specific immune response. These cells generally express little cytotoxicity unless activated. The present work was intended to determine if peritoneal macrophages collected from patients on Continuous Ambulatory Peritoneal Dialysis (CAPD) during episodes of peritonitis were active against human tumor cell lines without further in vitro stimulation. We also compared macrophage antitumor potential with effectiveness of drugs used in cancer therapy (taxol and suramin). Conditioned medium (CM) of macrophages collected during inflammation-free periods did not exhibit cytostatic and cytotoxic activity against both tumor (A549 and HTB44) and non-transformed (BEAS-2B and CRL2190) cells. Exposure of tumor cells to CM of macrophages harvested during peritonitis resulted in significant suppression of proliferation, impairment of viability and induction of apoptosis, in contrast to non-transformed cells, which remained unaffected. The efficacy of CM of inflammatory macrophages as an antitumor agent appeared to be comparable to cytostatic and cytotoxic potency of taxol and suramin or, in the case of HTB44 cells, even higher. The results obtained suggest that activated human macrophages might represent a useful tool for cancer immunotherapy.
authors.affiliation: Department of General Biochemistry, Faculty of Biotechnology, Jagiellonian University, Cracow, Poland. bohdan@mol.uj.edu.pl
authors.forename: Bohdan
authors.initials: B
authors.lastname: Turyna
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Jurek
authors.forename: Kamil
authors.initials: K
authors.lastname: Gotfryd
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Siaśkiewicz
authors.forename: Piotr
authors.initials: P
authors.lastname: Kubit
authors.forename: Andrzej
authors.initials: A
authors.lastname: Klein
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D002460:Cell Line; D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D017077:Culture Media, Conditioned / Q000494:pharmacology; D006801:Humans; D017737:Macrophages, Peritoneal / Q000276:immunology* / Q000648:ultrastructure; D009369:Neoplasms / Q000276:immunology*; D017239:Paclitaxel / Q000494:pharmacology; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010538:Peritonitis / Q000150:complications / Q000276:immunology*; D013498:Suramin / Q000494:pharmacology; D014511:Uremia / Q000150:complications* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D017077:Culture Media, Conditioned; D013498:Suramin; D017239:Paclitaxel